强化降压对CKD患者肾小管损伤的影响:SPRINT纵向亚组分析
该研究对SPRINT试验中978例CKD患者进行纵向亚组分析,比较强化降压(SBP<120mmHg)与标准降压(SBP<140mmHg)对8种尿肾小管生物标志物的影响。结果显示强化组eGFR下降更明显,但肾小管损伤标志物均未升高,提示eGFR下降主要反映血流动力学变化而非肾小管细胞损伤。
要点
- 强化降压未增加CKD患者肾小管损伤标志物水平。
- 强化组eGFR较标准组下降更明显,但肾小管功能标志物反而更低。
- eGFR下降可能主要反映血流动力学变化而非肾小管损伤。
核心结论
- 在SPRINT的CKD参与者中,强化SBP降压未增加8种尿肾小管细胞损伤标志物的水平,尽管eGFR下降更明显。
- 这些发现支持强化降压组eGFR下降主要反映血流动力学变化而非肾小管细胞内在损伤的假说。
研究设计与样本
- SPRINT临床试验的纵向亚组分析,随机抽取基线时eGFR<60mL/min/1.73m2的CKD患者。
- 共纳入978例参与者,强化组519例,标准组459例,平均年龄72±9岁,基线eGFR为46.1±9.4mL/min/1.73m2。
主要发现
- 与标准组相比,强化组第1年和第4年eGFR分别低2.9和3.3mL/min/1.73m2。
- 第1年和第4年时,强化组8种肾小管标志物水平均未高于标准组。
- 第1年时,强化组两种肾小管功能标志物B2M和A1M分别较标准组低29%(95%CI,10%-43%)和24%(95%CI,10%-36%)。
关键数值与推荐
- 强化降压目标为收缩压<120mmHg,标准降压目标为收缩压<140mmHg。
- CKD定义为基线时使用CKD-EPI肌酐-胱抑素C方程计算的eGFR<60mL/min/1.73m2。
临床怎么用
- 对于CKD患者,强化降压至SBP<120mmHg未增加肾小管损伤,eGFR下降可能为血流动力学效应。
- 临床解读强化降压后eGFR下降时,应结合肾小管损伤标志物综合评估,避免误判为肾实质损伤。
局限性
- 研究排除了糖尿病患者。
- 晚期CKD参与者较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Random assignment to the intensive systolic blood pressure (SBP) arm (<120mmHg) in the Systolic Blood Pressure Intervention Trial (SPRINT) resulted in more rapid declines in estimated glomerular filtration rates (eGFRs) than in the standard arm (SBP<140mmHg). Whether this change reflects hemodynamic effects or accelerated intrinsic kidney damage is unknown. STUDY DESIGN: Longitudinal subgroup analysis of clinical trial participants. SETTINGS & PARTICIPANTS: Random sample of SPRINT participants with prevalent chronic kidney disease (CKD) defined as eGFR<60mL/min/1.73m2 by the CKD-EPI (CKD Epidemiology Collaboration) creatinine-cystatin C equation at baseline. OUTCOMES & MEASUREMENTS: Urine biomarkers of tubule function (β2-microglobulin [B2M], α1-microglobulin [A1M]), and uromodulin), injury (interleukin 18, kidney injury molecule 1, and neutrophil gelatinase-associated lipocalin), inflammation (monocyte chemoattractant protein 1), and repair (human cartilage glycoprotein 40) at baseline, year 1, and year 4. Biomarkers were indexed to urine creatinine concentration and changes between arms were evaluated using mixed-effects linear models and an intention-to-treat approach. RESULTS: 978 SPRINT participants (519 in the intensive and 459 in the standard arm) with prevalent CKD were included. Mean age was 72±9 years and eGFR was 46.1±9.4mL/min/1.73m2 at baseline. Clinical characteristics, eGFR, urinary albumin-creatinine ratio, and all 8 biomarker values were similar across arms at baseline. Compared to the standard arm, eGFR was lower by 2.9 and 3.3mL/min/1.73m2 in the intensive arm at year 1 and year 4. None of the 8 tubule marker levels was higher in the intensive arm compared to the standard arm at year 1 or year 4. Two tubule function markers (B2M and A1M) were 29% (95% CI, 10%-43%) and 24% (95% CI, 10%-36%) lower at year 1 in the intensive versus standard arm, respectively. LIMITATIONS: Exclusion of persons with diabetes, and few participants had advanced CKD. CONCLUSIONS: Among participants with CKD in SPRINT, random assignment to the intensive SBP arm did not increase any levels of 8 urine biomarkers of tubule cell damage despite loss of eGFR. These findings support the hypothesis that eGFR declines in the intensive arm of SPRINT predominantly reflect hemodynamic changes rather than intrinsic damage to kidney tubule cells.
引用
- Malhotra R, Craven T, Ambrosius WT, et al. Effects of Intensive Blood Pressure Lowering on Kidney Tubule Injury in CKD: A Longitudinal Subgroup Analysis in SPRINT. Am J Kidney Dis. 2018. PMID: 30291012. doi:10.1053/j.ajkd.2018.07.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。